摘要
为研究抗菌肽CGA-N46对皮肤感染克柔念珠菌小鼠的治疗效果,用克柔念珠菌感染免疫抑制小鼠制备感染模型,采取皮肤病变观察、皮下脓疱液和痂皮分离真菌,确定建模是否成功。对克柔念珠菌感染小鼠模型分别涂抹4 mg/mL和8 mg/mL CGA-N46进行治疗,以成活率、有效率和组织病理变化判断CGA-N46治疗效果。结果表明,以2×108 CFU/mL克柔念珠菌菌悬液感染表皮可建立感染模型;4 mg/mL和8mg/mL CGA-N46均能提高克柔念珠菌感染小鼠成活率,对克柔念珠菌皮肤感染有缓解作用,其中8mg/mL CGA-N46治疗效果更好。结果证实,CGA-N46对克柔念珠菌临床感染有治疗效果,具有开发成新型抗真菌药物的潜力。
CGA-N46 is a novel antifungal peptide derived from human chromogranin A. The study was de- signed to evaluate its curative effect on the skin infection of mice. The skin infection model of mice infected with Candida krusei was set up successfully after being checked by skin symptom and C. krusei isolated from scurf and coats. The CGA-N46 at two different concentrations, 4 mg/mL and 8 mg/mL CGA-N46, were applied for treatment respectively. The survival rate and the relieving rates were calculated, and the skin pathological lesions with HE staining were observed. The results showed that the lowest concentra- tion of infection with Candida krusei was 2 X 108 CFU/mL CGA-N46 could increase the survival rate of C. krusei-infected mice, and relieve the infection symptoms at a dose-dependent pattern. In conclusion, CGA-N46 had commendable curative effect on clinical infection of C. krusei and had potency to be a novel antifungal drugs.
出处
《动物医学进展》
北大核心
2015年第6期111-115,共5页
Progress In Veterinary Medicine
基金
国家自然科学基金项目(31071922)
